Body composition and arsenic metabolism: A cross-sectional analysis in the Strong Heart Study

Environmental Health: A Global Access Science Source

Volumn 12, Issue 1, 2013, Pages

  Gribble, Matthew O ^a   Crainiceanu, Ciprian M ^b   Howard, Barbara V ^c,d   Umans, Jason G ^c,d   Francesconi, Kevin A ^e   Goessler, Walter ^e   Zhang, Ying ^f   Silbergeld, Ellen K ^b   Guallar, Eliseo ^a,g   Navas Acien, Ana ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

^d Delaware   (United States)

^e UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

American Indians; Arsenic; Arsenic metabolism; Arsenic species; Body mass index; Obesity; Strong Heart Study

Indexed keywords

ARSENIC; CACODYLIC ACID; METHANEARSONIC ACID; ORGANOARSENIC DERIVATIVE; WATER POLLUTANT;

ARSENIC; BIOMARKER; BODY MASS; BODY SIZE; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; ESTER; FAT; HEALTH IMPACT; HEALTH SURVEY; METABOLISM; NUMERICAL MODEL; OBESITY; RURAL POPULATION; SOCIOECONOMIC CONDITIONS; TEMPORAL ANALYSIS; URINE;

ADULT; AGED; ARSENIC METABOLISM; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY SIZE; CROSS-SECTIONAL STUDY; FAT FREE MASS; FEMALE; HUMAN; IMPEDANCE; LIMIT OF DETECTION; MALE; METABOLISM; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; UNITED STATES; URINALYSIS; WAIST CIRCUMFERENCE; AMERICAN INDIAN; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; URINE; WATER POLLUTANT;

ARIZONA; NORTH DAKOTA; OKLAHOMA [UNITED STATES]; SOUTH DAKOTA; UNITED STATES;

ADIPOSITY; AGED; ARIZONA; ARSENIC; ARSENICALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MASS SPECTROMETRY; MIDDLE AGED; MIDWESTERN UNITED STATES; WATER POLLUTANTS, CHEMICAL;

EID: 84891848601     PISSN: None     EISSN: 1476069X     Source Type: Journal    
DOI: 10.1186/1476-069X-12-107     Document Type: Article

References (69)

1. Some Drinking-Water Disinfectants and Contaminants, including Arsenic. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol. 84 Lyon, France: WHO Press 2004
2. A market basket survey of inorganic arsenic in food. Schoof RA, Yost LJ, Eickhoff J, Crecelius EA, Cragin DW, Meacher DM, Menzel DB, Food Chem Toxicol 1999 37 839 846 10.1016/S0278-6915(99)00073-3 10506007 (Pubitemid 29472435)
3. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ, Envi Health Perspect 1999 107 663 667 10.1289/ehp.99107663 (Pubitemid 29412779)
4. Worldwide Occurrences of Arsenic in Ground Water. Nordstrom DK, Science 2002 296 2143 2145 10.1126/science.1072375 12077387
5. A review of the source, behaviour and distribution of arsenic in natural waters. Smedley PL, Kinniburgh DG, Appl Geochem 2002 17 517 568 10.1016/S0883-2927(02)00018-5 (Pubitemid 34290137)
6. Mechanisms of arsenic biotransformation. Vahter M, Toxicology 2002 181-182 211 217 (Pubitemid 36015701)
7. Methylation study of a population environmentally exposed to arsenic in drinking water. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE, Envi Health Perspect 1996 104 620 628 10.1289/ehp.96104620 (Pubitemid 26245412)
8. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, Wei ML, Chen HC, Yang HT, Leu LC, Chu TH, Chen-Wu C, Yang MH, Chen CJ, Mutat Res 1997 386 197 207 10.1016/S1383-5742(97)00005-7 9219558 (Pubitemid 27286293)
9. Urinary creatinine and arsenic metabolism. Gamble MV, Liu X, Envi Health Perspect 2005 113 442 A443 A442; author reply
10. Association between body mass index and arsenic methylation efficiency in adult women from southwest U.S. and northwest Mexico. Gomez-Rubio P, Roberge J, Arendell L, Harris RB, O'Rourke MK, Chen Z, Cantu-Soto E, Meza-Montenegro MM, Billheimer D, Lu Z, Klimecki WT, Toxicol Appl Pharmacol 2011 252 176 82 10.1016/j.taap.2011.02.007 21320519
11. Urine arsenic concentrations and species excretion patterns in American Indian communities over a 10-year period: the Strong Heart Study. Navas-Acien A, Umans JG, Howard BV, Goessler W, Francesconi KA, Crainiceanu CM, Silbergeld EK, Guallar E, Envi Health Perspect 2009 117 1428 1433
12. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Vahter M, Toxicol Lett 2000 112-113 209 217 (Pubitemid 30138125)
13. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, Gamble MV, Graziano JH, Cancer Epid Bio Prev 2007 16 1270 1278 10.1158/1055-9965.EPI-06-0676 (Pubitemid 46984970)
14. Arsenic exposure at low-to-moderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Chen Y, Parvez F, Gamble M, Islam T, Ahmed A, Argos M, Graziano JH, Ahsan H, Toxicol Appl Pharmacol 2009 239 184 192 10.1016/j.taap.2009.01.010 19371619
15. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Valenzuela OL, Drobna Z, Hernandez-Castellanos E, Sanchez-Pena LC, Garcia-Vargas GG, Borja-Aburto VH, Styblo M, Del Razo LM, Toxicol Appl Pharmacol 2009 239 200 207 10.1016/j.taap.2009.06.007 19538983
16. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, Rey OA, Biggs ML, Hopenhayn C, Moore LE, Hoang BK, Smith AH, J Occup Environ Med 2006 48 478 488 10.1097/01.jom.0000200982.28276.70 16688004 (Pubitemid 43772338)
17. Exposure, metabolism, and health effects of arsenic in residents from arsenic-contaminated groundwater areas of Vietnam and Cambodia: a review. Agusa T, Kunito T, Kubota R, Inoue S, Fujihara J, Minh TB, Ha NN, Tu NP, Trang PT, Chamnan C, Takeshita H, Iwata H, Tuyen BC, Viet PH, Tana TS, Tanabe S, Rev Environ Health 2010 25 193 220 21038756
18. Arsenic methylation and skin cancer risk in southwestern Taiwan. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Chao SC, Lee JY, Christiani DC, J Occup Environ Med 2003 45 241 248 10.1097/01.jom.0000058336.05741.e8 12661181 (Pubitemid 36347799)
19. Arsenic methylation capacity and skin cancer. Yu RC, Hsu KH, Chen CJ, Froines JR, Cancer Epi Bio Prev 2000 9 1259 1262
20. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, Basu A, Porter KE, Hubbard A, Bates MN, Smith MT, Smith AH, Toxicol Appl Pharmacol 2010 247 138 145 10.1016/j.taap.2010.06.006 20600216
21. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Huang YK, Huang YL, Hsueh YM, Yang MH, Wu MM, Chen SY, Hsu LI, Chen CJ, Cancer Causes Control 2008 19 829 839 10.1007/s10552-008-9146-5 18351295
22. Plasma folate level, urinary arsenic methylation profiles, and urothelial carcinoma susceptibility. Huang YK, Pu YS, Chung CJ, Shiue HS, Yang MH, Chen CJ, Hsueh YM, Food Chem Toxicol 2008 46 929 938 10.1016/j.fct.2007.10.017 18054417 (Pubitemid 351172563)
23. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM, Toxicol Appl Pharmacol 2007 218 135 142 10.1016/j.taap.2006.10.022 17173945 (Pubitemid 46177165)
24. Urinary arsenic methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-hyperendemic areas in southwestern Taiwan. Huang YL, Hsueh YM, Huang YK, Yip PK, Yang MH, Chen CJ, Sci Total Environ 2009 407 2608 2614 10.1016/j.scitotenv.2008.12.061 19187952
25. Role of metabolism in arsenic toxicity. Vahter M, Concha G, Pharmacol Toxicol 2001 89 1 5 10.1034/j.1600-0773.2001.d01-128.x (Pubitemid 32664563)
26. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Drobna Z, Naranmandura H, Kubachka KM, Edwards BC, Herbin-Davis K, Styblo M, Le XC, Creed JT, Maeda N, Hughes MF, Thomas DJ, Chem Res Toxicol 2009 22 1713 1720 10.1021/tx900179r 19691357
27. Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Drobna Z, Waters SB, Walton FS, LeCluyse EL, Thomas DJ, Styblo M, Toxicol Appl Pharmacol 2004 201 166 177 10.1016/j.taap.2004.05.004 15541756 (Pubitemid 39487164)
28. Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Hirano S, Cui X, Li S, Kanno S, Kobayashi Y, Hayakawa T, Shraim A, Arch Toxicol 2003 77 305 312 12799770 (Pubitemid 36819260)
29. Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. Medina-Diaz IM, Estrada-Muniz E, Reyes-Hernandez OD, Ramirez P, Vega L, Elizondo G, Toxicol Appl Pharmacol 2009 239 162 168 10.1016/j.taap.2008.11.009 19084030
30. Oxidation and methylation status determine the effects of arsenic on the mitotic apparatus. Kligerman AD, Doerr CL, Tennant AH, Mol Cell Biochem 2005 279 113 121 10.1007/s11010-005-8283-3 16283520 (Pubitemid 43055149)
31. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A, Toxicol Appl Pharmacol 2004 198 458 467 10.1016/j.taap.2003.10.023 15276427 (Pubitemid 38969975)
32. Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Hernandez A, Marcos R, Pharmacogenomics 2008 9 1113 1132 10.2217/14622416.9.8.1113 18681785
33. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. Wood TC, Salavagionne OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM, J Biol Chem 2006 281 7364 7373 10.1074/jbc.M512227200 16407288 (Pubitemid 43847506)
34. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M, Exp Biol Med (Maywood) 2007 232 3 13 17202581 (Pubitemid 46089936)
35. Manipulation of expression of arsenic (+3 oxidation state) methyltransferase in cultured cells. Drobna Z, Styblo M, Thomas DJ, Curr Protoc Toxicol 2010 4 4 35
36. A review on environmental factors regulating arsenic methylation in humans. Tseng CH, Toxicol Appl Pharmacol 2009 235 338 350 10.1016/j.taap.2008. 12.016 19168087
37. Folate, cobalamin, cysteine, homocysteine, and arsenic metabolism among children in Bangladesh. Hall MN, Liu X, Slavkovich V, Ilievski V, Pilsner JR, Alam S, Factor-Litvak P, Graziano JH, Gamble MV, Environ Health Perspect 2009 117 825 831 10.1289/ehp.0800164 19479028
38. Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Lindberg AL, Kumar R, Goessler W, Thirumaran R, Gurzau E, Koppova K, Rudnai P, Leonardi G, Fletcher T, Vahter M, Environ Health Perspect 2007 115 1081 1086 10.1289/ehp.10026 17637926 (Pubitemid 47317076)
39. Consumption of folate-related nutrients and metabolism of arsenic in Bangladesh. Heck JE, Gamble MV, Chen Y, Graziano JH, Slavkovich V, Parvez F, Baron JA, Howe GR, Ahsan H, Am J Clin Nutr 2007 85 1367 1374 17490975 (Pubitemid 46740481)
40. Variability in biomarkers of arsenic exposure and metabolism in adults over time. Kile ML, Hoffman E, Hsueh YM, Afroz S, Quamruzzaman Q, Rahman M, Mahiuddin G, Ryan L, Christiani DC, Environ Health Perspect 2009 117 455 460 19337522
41. The relationship between obesity, insulin and arsenic methylation capability in Taiwan adolescents. Su CT, Lin HC, Choy CS, Huang YK, Huang SR, Hsueh YM, Sci Total Environ 2012 414 152 158 22104380
42. Selection of measures in epidemiologic studies of the consequences of obesity. Stevens J, McClain JE, Truesdale KP, Int J Obes (Lond) 2008 32 Suppl 3 60 S66 18695656
43. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ, Howard BV, Am J Epidemiol 1990 132 1141 1155 2260546
44. The Strong Heart Study manual: chapter 5: clinical examination. Modified May 2, 2003. 2012 http://strongheart.ouhsc.edu/manual/PhaseI/Chapter%205.pdf
45. Urine arsenic and hypertension in US adults: the 2003-2008 national health and nutrition examination survey. Jones MR, Tellez-Plaza M, Sharrett AR, Guallar E, Navas-Acien A, Epidemiology 2011 22 153 161 10.1097/EDE. 0b013e318207fdf2 21206367
46. Body composition in Pima Indians: validation of bioelectrical resistance. Rising R, Swinburn B, Larson K, Ravussin E, Am J Clin Nutr 1991 53 594 598 2000812 (Pubitemid 21917628)
47. Predictive accuracy of bioelectrical impedance in estimating body composition of Native American women. Stolarczyk LM, Heyward VH, Hicks VL, Baumgartner RN, Am J Clin Nutr 1994 59 964 970 8172101 (Pubitemid 24138365)
48. Arsenic species and selected metals in human urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based epidemiological study. Scheer J, Findenig S, Goessler W, Francesconi K, Howard B, Umans J, Pollak J, Tellez-Plaza M, Silbergeld E, Guallar E, Navas-Acien A, Analytical Methods 2012 4 406 413 10.1039/c2ay05638k 22685491
49. Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study. Gribble MO, Howard BV, Umans JG, Shara NM, Francesconi KA, Goessler W, Crainiceanu CM, Silbergeld EK, Guallar E, Navas-Acien A, Am J Epidemiol 2012 176 865 874 10.1093/aje/kws153 23097256
50. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Cox C, Chu H, Schneider MF, Munoz A, Stat Med 2007 26 4352 4374 10.1002/sim.2836 17342754 (Pubitemid 47430381)
51. Beta regression for modelling rates and proportions. Ferrari SL, Cribari-Neto F, J Appl Stat 2004 31 799 815 10.1080/0266476042000214501 (Pubitemid 39173835)
52. Modelling compositional data using Dirichlet regression models. Hijazi RH, Jernigan RW, J Appl Probab Stat 2009 4 77 91
53. Interviewer variability in anthropometric measurements and estimates of body composition. Klipstein-Grobusch K, Georg T, Boeing H, Int J Epidemiol 1997 26 Suppl 1 174 S180 9126545
54. Bioelectrical impedance analysis in body composition measurement: National Institutes of Health Technology Assessment Conference Statement. Am J Clin Nutr 1996 64 524S 532S 8780375
55. Exposure measurement error in time-series studies of air pollution: concepts and consequences. Zeger SL, Thomas D, Dominici F, Samet JM, Schwartz J, Dockery D, Cohen A, Environ Health Perspect 2000 108 419 426 10.1289/ehp.00108419 10811568 (Pubitemid 30421019)
56. Arsenic methylation efficiency increases during the first trimester of pregnancy independent of folate status. Gardner RM, Nermell B, Kippler M, Grander M, Li L, Ekstrom EC, Rahman A, Lonnerdal B, Hoque AM, Vahter M, Reprod Toxicol 2011 31 210 218 10.1016/j.reprotox.2010.11.002 21078382
57. Profile of urinary arsenic metabolites during pregnancy. Hopenhayn C, Huang B, Christian J, Peralta C, Ferreccio C, Atallah R, Kalman D, Environ Health Perspect 2003 111 1888 1891 10.1289/ehp.6254 14644662 (Pubitemid 37541199)
58. Composition of gestational weight gain impacts maternal fat retention and infant birth weight. Butte NF, Ellis KJ, Wong WW, Hopkinson JM, Smith EO, Am J Obstet Gynecol 2003 189 1423 1432 10.1067/S0002-9378(03)00596-9 14634581 (Pubitemid 37542185)
59. Body fat and water changes during pregnancy in women with different body weight and weight gain. Lederman SA, Paxton A, Heymsfield SB, Wang J, Thornton J, Pierson RN Jr, Obstet Gynecol 1997 90 483 488 10.1016/S0029-7844(97)00355-4 9380301 (Pubitemid 27407382)
60. Arsenic activates endothelin-1 gi protein-coupled receptor signaling to inhibit stem cell differentiation in adipogenesis. Klei LR, Garciafigueroa DY, Barchowsky A, Toxicol Sci 2013 131 512 520 10.1093/toxsci/kfs323 23152186
61. Low-level arsenite activates the transcription of genes involved in adipose differentiation. Salazard B, Bellon L, Jean S, Maraninchi M, El-Yazidi C, Orsiere T, Margotat A, Botta A, Berge-Lefranc JL, Cell Biol Toxicol 2004 20 375 385 10.1007/s10565-004-1471-1 15868481 (Pubitemid 40767693)
62. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Wauson EM, Langan AS, Vorce RL, Toxicol Sci 2002 65 211 219 10.1093/toxsci/65.2.211 11812925 (Pubitemid 34121113)
63. Association between arsenic suppression of adipogenesis and induction of CHOP10 via the endoplasmic reticulum stress response. Hou Y, Xue P, Woods CG, Wang X, Fu J, Yarborough K, Qu W, Zhang Q, Andersen ME, Pi J, Environ Health Perspect 2013 121 237 243 23221991
64. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S, Am J Clin Nutr 1983 37 478 494 6829490 (Pubitemid 13086433)
65. S-adenosylmethionine: jack of all trades and master of everything? Loenen WA, Biochem Soc Trans 2006 34 330 333 16545107
66. The metabolic burden of creatine synthesis. Brosnan JT, da Silva RP, Brosnan ME, Amino Acids 2011 40 1325 1331 10.1007/s00726-011-0853-y 21387089
67. Relationship of creatinine and nutrition with arsenic metabolism. Gamble MV, Hall MN, Environ Health Perspect 2012 120 145 A146
68. Unraveling arsenic-glutathione connections. Thomas DJ, Toxicol Sci 2009 107 309 311 19074764
69. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G, Stat Med 2008 27 1133 1163 10.1002/sim.3034 17886233 (Pubitemid 351395448) Kidney Diseases